- Alnylam to discuss Huntington’s disease program at October 26 RNAi Roundtable - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics ...
Below is a list of sell-side analysts actively covering Alnylam ...
Feb 15, 2024 Feb 15, 2024 − Achieved Fourth Quarter and Full Year 2023 Global Net Product Revenues of $346 Million and $1,241 Million, Respectively, Representing 39% Annual Growth Compared to 2022 – − ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 30, 2026-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology ...
– Qfitlia Becomes the Sixth Alnylam-Discovered RNAi Therapeutic Approved by U.S. FDA and First and Only to Treat Hemophilia A or B With or Without Inhibitors – ...
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity Oct 28, 2021 − Achieved Third Quarter 2021 Combined Net Product Revenues of $167 Million for ...
Net product revenues increased 35% during the third quarter 2023, as compared to the prior year, and 33% at CER. The increase is primarily related to growth in our TTR product revenues driven by the ...
Net product revenues increased 32% and 35% at actual currency during the three and twelve months ended December 31, 2022, respectively, compared to the same periods in 2021, and 41% and 43% at CER, ...
– Launching on World Heart Day, Retired Professional Football Player Pete Shaw Shares How Symptoms Attributed to Football and Aging Led to a Delayed ATTR-CM Diagnosis – – ‘Play by Play’ Uses Sports to ...
– At 9 Months, Vutrisiran Met Primary and All Secondary Endpoints, with Statistically Significant Improvements in Neuropathy, Quality of Life (QoL), and Gait Speed, Relative to Placebo – – In Majority ...
– ONPATTRO Indicated for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (hATTR amyloidosis) in Adults with Stage 1 or Stage 2 Polyneuropathy – – First-Ever RNAi Therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results